PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23317245-1	2012	We conducted this study to detect associations between XRCC1 Arg399Gln and XPD Lys751Gln genotypes and survival of colorectal cancer patients treated with 5-FU/oxalipatin chemotherapy.	Fluorouracil	155-159	X-ray repair cross complementing 1	Homo sapiens	55-60	
28149883-5	2016	The reviewed paper by Sebio and colleagues report a study that links polymorphisms in the DNA repair gene XRCC1 with response to neoadjuvant 5-Fluorouracil treatment in rectal cancer patients.	Fluorouracil	141-155	X-ray repair cross complementing 1	Homo sapiens	106-111	
23894404-8	2013	CONCLUSION: The XPD and XRCC1 allelic variants may be prognostic markers for CRC patients receiving 5-FU based chemotherapy.	Fluorouracil	100-104	X-ray repair cross complementing 1	Homo sapiens	24-29	
32426369-10	2020	But, XRCC1 knockdown could significantly improve the sensitivity of CD133+GBC-SD cells to 5-Fluorouracil via promoting cell necrosis and apoptosis.	Fluorouracil	90-104	X-ray repair cross complementing 1	Homo sapiens	5-10	
29117108-4	2017	Thus, this study was aimed to examine whether XRCC1 plays a role in the 5-FU/AMPK agonist (AICAR)-induced cytotoxic effect on CRC and the underlying mechanisms.	Fluorouracil	72-76	X-ray repair cross complementing 1	Homo sapiens	46-51	
29117108-6	2017	It was shown that 5-FU increases the XRCC1 expression in HCT-116 cells and then affects the cell survival through CXCR4/Akt signaling.	Fluorouracil	18-22	X-ray repair cross complementing 1	Homo sapiens	37-42	
29117108-7	2017	Moreover, 5-FU combined with AICAR further result in more survival inhibition in HCT-116 cells, accompanied with reduced CXCR4/Akt signaling activity and XRCC1 expression.	Fluorouracil	10-14	X-ray repair cross complementing 1	Homo sapiens	154-159	
29117108-8	2017	These results elucidate the role and mechanism of XRCC1 in the drug resistance of HCT-116 cells to 5-FU.	Fluorouracil	99-103	X-ray repair cross complementing 1	Homo sapiens	50-55	
22580644-8	2012	CONCLUSIONS: This study is first to report that the XRCC1 and XRCC3 gene polymorphisms are useful as a surrogate marker of clinical outcome in colorectal cancer with 5-FU/oxaliplatin combination chemotherapy in the Chinese population.	Fluorouracil	166-170	X-ray repair cross complementing 1	Homo sapiens	52-57	
23317245-8	2012	In conclusion, it is suggested that the XRCC1 Arg399Gln and XPD Lys751Gln polymorphisms should be routinely assessed to determine colorectal patients who are more likely to benefit from 5-FU/oxalipatin chemotherapy.	Fluorouracil	186-190	X-ray repair cross complementing 1	Homo sapiens	40-45	
21167658-10	2012	Germline thymidylate synthase and XRCC1 polymorphisms might be useful as predictive markers of rectal tumor response to neoadjuvant chemoradiotherapy with 5-fluorouracil.	Fluorouracil	155-169	X-ray repair cross complementing 1	Homo sapiens	34-39	
17273745-0	2007	Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan.	Fluorouracil	232-246	X-ray repair cross complementing 1	Homo sapiens	116-150	
17558308-0	2007	Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer.	Fluorouracil	135-149	X-ray repair cross complementing 1	Homo sapiens	38-43	
17558308-14	2007	CONCLUSION: The DNA repair enzyme XRCC1 is a potential treatment predictor for the outcome and survival of anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of invasive breast cancer.	Fluorouracil	155-169	X-ray repair cross complementing 1	Homo sapiens	34-39	
21468552-7	2011	A similar reaction has also been observed in patients with the XRCC1 Arg399Gln polymorphism, while patients with the GSTP1 Ile105Val polymorphism have an improved response to oxaliplatin/5FU therapy.	Fluorouracil	187-190	X-ray repair cross complementing 1	Homo sapiens	63-68	
21029695-10	2010	CONCLUSION: Genetic polymorphisms of ERCC1-118, XRCC1-399 and GSTP1-105 are associated with TTP and OS of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based combination chemotherapy as the first-line chemotherapy.	Fluorouracil	164-168	X-ray repair cross complementing 1	Homo sapiens	48-53	
17273745-4	2007	In the OXA + 5-FU group, patients with the TS 5" single nucleotide polymorphism and/or XRCC1 genotypes favourable to treatment had a better TTP (log-rank p=0.02).	Fluorouracil	13-17	X-ray repair cross complementing 1	Homo sapiens	87-92	
11712813-8	2001	The data suggest that the polymorphism in exon 10 of the XRCC1 gene may be associated with resistance to oxaliplatin/5-FU chemotherapy in advanced colorectal cancer.	Fluorouracil	117-121	X-ray repair cross complementing 1	Homo sapiens	57-62